Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1499
Gene Symbol: CTNNB1
CTNNB1
0.010 Biomarker disease BEFREE Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma. 26883469 2016
Entrez Id: 2150
Gene Symbol: F2RL1
F2RL1
0.010 Biomarker disease BEFREE Our finding also suggests that PAR2 might serve as a therapeutic target for metastatic lung adenocarcinoma and a potential biomarker for predicting the prognosis of lung adenocarcinoma. 30321617 2019
Entrez Id: 2026
Gene Symbol: ENO2
ENO2
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 9468
Gene Symbol: PCYT1B
PCYT1B
0.010 Biomarker disease BEFREE Targeting β-tubulin/CCT-β complex induces apoptosis and suppresses migration and invasion of highly metastatic lung adenocarcinoma. 31400757 2019
Entrez Id: 4654
Gene Symbol: MYOD1
MYOD1
0.010 Biomarker disease BEFREE Expression of ERCC1, TYMS, TUBB3, non‑muscle myosin II, myoglobin and MyoD1 genes was associated with decreased survival in patients with metastatic lung adenocarcinoma. 25573098 2015
Entrez Id: 5133
Gene Symbol: PDCD1
PDCD1
0.010 Biomarker disease BEFREE We report a patient with brain metastatic lung adenocarcinoma in whom fatal myocarditis developed after sequential use of PD-1 and PD-L1 inhibitors. 31022941 2019
Entrez Id: 10576
Gene Symbol: CCT2
CCT2
0.010 Biomarker disease BEFREE Targeting β-tubulin/CCT-β complex induces apoptosis and suppresses migration and invasion of highly metastatic lung adenocarcinoma. 31400757 2019
Entrez Id: 3799
Gene Symbol: KIF5B
KIF5B
0.010 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 23583
Gene Symbol: SMUG1
SMUG1
0.010 Biomarker disease BEFREE We investigated the predictive role of dual-time-point <sup>18</sup>F-FDG PET/CT to distinguish primary and metastatic lung adenocarcinoma in SPN. 29714664 2018
Entrez Id: 100302126
Gene Symbol: MIR1471
MIR1471
0.010 Biomarker disease BEFREE The 4 most significantly deregulated miRNAs (miR-145, miR-214, miR-9* and miR-1471) were validated in the additional 43 samples (35 primary and 8 brain metastatic lung adenocarcinoma samples) using TaqMan quantitative PCR. 24026105 2013
Entrez Id: 5617
Gene Symbol: PRL
PRL
0.010 Biomarker disease BEFREE Postoperative pathology and western blotting disclosed a prolactin-positive metastatic lung adenocarcinoma. 30137505 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Between June 2014 and May 2015, 168 plasma samples were collected monthly from 20 patients with metastatic lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation receiving gefitinib therapy. 28599456 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and anaplastic lymphoma kinase (ALK) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma. 23495083 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. 24835218 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Low primary SUV<sub>max</sub>, low serum CEA level, female and never smoker were four prognostic factors suggestive of good response to TKI in mutated EGFR metastatic lung adenocarcinoma. 31846863 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Smoking during treatment is a negative prognostic factor in metastatic lung adenocarcinoma with an EGFR mutation. 27371767 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy. 31634655 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Transabdominal hysterectomy and bilateral salpingo-oophorectomy showed solitary intramyometrial metastatic lung adenocarcinoma with a second-site T790M gatekeeper mutation in exon 20 of the EGFR gene. 29094453 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Our data support the recommendation that EGFR mutation status should be defined in all cases of locally advanced or metastatic lung adenocarcinoma. 27105879 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE The studies, phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (LUX-Lung 3) and a randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation (LUX-Lung 6) investigated first-line afatinib versus platinum-based chemotherapy in epidermal growth factor receptor gene (EGFR) mutation-positive patients with NSCLC and included patients with brain metastases; prespecified subgroup analyses are assessed in this article. 26823294 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE We identified oncogenic and drug-sensitive EGFR-KDD that is recurrent in lung, brain, and soft-tissue cancers and documented that a patient with metastatic lung adenocarcinoma harboring the EGFR-KDD derived significant antitumor response from treatment with the EGFR inhibitor afatinib. 26286086 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. 23816960 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Our study confirmed the efficacy and safety of first line erlotinib monotherapy in Caucasian patients with locally advanced or metastatic lung adenocarcinoma carrying activating EGFR mutations based on the screening with the approved companion diagnostic procedure. 29801465 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Genetic testing revealed two additional EGFR T790M germline carriers, one of which was subsequently diagnosed with metastatic lung adenocarcinoma. 24736080 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Here, we report the case of a 72-year-old, never-smoker female diagnosed with multiple metastatic lung adenocarcinoma (cT2aN2M1) harboring EGFR mutations in exon 21 (L858R) of the primary lesion. 30022837 2018